US 11,905,292 B2
Process and intermediates for preparing a JAK inhibitor
Jiacheng Zhou, Newark, DE (US); Shili Chen, Newark, DE (US); Pingli Liu, Wilmington, DE (US); David J. Meloni, Bear, DE (US); James M. Parks, Newark, DE (US); Yongchun Pan, Wilmington, DE (US); Naijing Su, Hockessin, DE (US); Michael Xia, Wilmington, DE (US); and Weiguo Liu, Wilmington, DE (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Aug. 17, 2021, as Appl. No. 17/404,613.
Claims priority of provisional application 63/217,498, filed on Jul. 1, 2021.
Claims priority of provisional application 63/214,012, filed on Jun. 23, 2021.
Claims priority of provisional application 63/067,097, filed on Aug. 18, 2020.
Prior Publication US 2022/0056035 A1, Feb. 24, 2022
Int. Cl. C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 69 Claims
 
1. A process of preparing ruxolitinib, or a salt thereof, comprising:
reacting a compound of formula 3:

OG Complex Work Unit Chemistry
or a salt thereof, with a reagent which is a salt of formula 2a:

OG Complex Work Unit Chemistry
wherein X− is a counter anion.